Pioneering diagnostics

Biomarkers

The discovery of new biomarkers will make it possible for patients to receive more personalized care based on their genetic profile, so that doctors can prescribe treatments that are perfectly targeted and therefore more effective.

bioMérieux has programs to discover and validate new biomarkers for infectious and cardiovascular diseases and cancer. Our research is enhanced by partnerships with leading clinical research centers.

Institut Mérieux and Institut Pasteur

Within the scope of a 2009 collaboration agreement between Institut Mérieux and Institut Pasteur, teams from bioMérieux and Institut Pasteur are working together on six projects.
Their primary aim is to characterize the different phases of infectious diseases by studying patients’ immune response in order to help clinicians better understand the disease and determine the best course of action.  
One example is developing new biomarkers to be used in cases of sepsis to:

  • establish the prognostic evaluation for the patient,   
  • obtain a stratification and determine the best treatment for each individual,  
  • detect possible organ failure extremely early to allow rapid intervention.

Uppsala Clinical Research Center

bioMérieux has a strategic agreement in the field of cardiovascular diseases with this Swedish research center to develop new biomarkers. This collaboration will enhance bioMérieux’s pipeline of innovative laboratory and Point-of-Care diagnostic tests to improve care for patients with heart disease.

 

Joint Research Laboratories

To conduct biomarker research, bioMérieux’s strategy of building partnerships with hospital research institutions has led to the creation of four joint research laboratories worldwide: at the Hospices Civils de Lyon, the Fudan University Cancer Center in Shanghai and the Immunology Institute in Singapore.

Hospices Civils de Lyon

  • The laboratory located at Lyon-Sud hospital (France) focuses on identifying new biomarkers for prostate cancer, with the aim of improving patient care throughout the different stages of the disease. The biomarkers should make it possible to confirm diagnosis when cancer is suspected, in addition to predicting the disease’s seriousness and progression in order to determine the most appropriate therapeutic strategy.
  • The joint research laboratory at Edouard Herriot hospital is focused on severe and acute infections such as sepsis. Researchers are working there to develop personalized treatment for patients based on:

Fudan University Cancer Center in Shanghai

In a joint laboratory in one of the largest cancer centers in China, researchers from bioMérieux and hospital oncologists are collaborating on the identification of tumor biomarkers from blood and tissues for the early detection of cancers and prediction of treatment efficacy.

ADNA Program

Participation in the ADNA program:

The ADNA program (Advanced Diagnostics for New Therapeutic Approaches) is based on the identification and development of biomarkers.
ADNA was designed to contribute to the development of personalized medical solutions, theranostics, in the areas of infectious diseases, cancer and rare genetic diseases, by making innovative products and services available to healthcare professionals. 

Coordinated by Institut Mérieux, the ADNA program brings together four key players:

  • bioMérieux and GenoSafe, specializing in diagnostics 
  • Généthon and Transgene, specializing in treatment  

Other partners contribute their expertise, including the French Atomic Energy Commission (CEA), the French National Scientific Research Center (CNRS), the Lyon University Hospitals (HCL), STMicroelectronics, and Claude Bernard University in Lyon (UCBL).